RxDoctor Payments Data

Marc Tack, DO

Infectious Disease · Kingston, NYNPI 1376582015

Payments from drug & device makers

$49,816in general payments, 2019–2025

Across 636 payments — averaging $78.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$37K
  • Shionogi Inc$3K
  • Viiv Healthcare Company$2K
  • Gilead$1K
  • Merck$1K
  • Amgen$1K
  • plus $5K from 41 others

What the payments were for

  • Consulting fees$9,54319%
  • Speaking & faculty fees$20,08540%
  • Travel & lodging$8,51217%
  • Food & beverage$11,55023%
  • Education$1260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,816 in reported general payments places this provider in the 85th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York

Medicare billing

Part B allowed, 2024
$442,310
Medicare patients
620
Services billed
80,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala124$540,644
RukobiaFostemsavir Tromethamine20$173,359
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf34$152,128
TivicayDolutegravir Sodium32$114,885
TriumeqAbacavir/Dolutegravir/Lamivudi18$87,486
DovatoDolutegravir Sodium/Lamivudine26$76,216
IsentressRaltegravir Potassium30$58,700
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$51,969
PrezistaDarunavir23$46,108
SelzentryMaraviroc13$44,258
JulucaDolutegravir/Rilpivirine12$41,304
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$40,694
EliquisApixaban30$31,599
VemlidyTenofovir Alafenamide17$28,447
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df25$16,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Vemlidy$1,277$621,060153 claims
Viiv Healthcare CompanyRukobia, Tivicay, Triumeq, Dovato, Juluca$1,914$493,250108 claims
PfizerSelzentry, Eliquis, Abrysvo$579$84,81071 claims
MerckIsentress$1,223$58,70030 claims
Lilly USA, LLCTrulicity$32$11,90712 claims
GSKShingrix$316$3,57016 claims
AstraZenecaNexium$411$3,51813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 799 infectious disease providers in New York.

Other infectious disease in Kingston

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →